Furthermore, because of the mutual dependence of MAPK- and PI3K-pathways, MEK inhibition causes a concomitant up-regulation of p-Akt [11], which is also known to increase survival, growth, radio- and chemoresistance of cells [12], thus counteracting tumor therapy. The gene discussed is MAP2K7; the disease is neoplasm.